ARS Pharmaceuticals GAAP EPS of -$0.52 misses by $0.05, revenue of $32.5M beats by $3.82M

* ARS Pharmaceuticals press release [https://seekingalpha.com/pr/20299947-ars-pharmaceuticals-reports-third-quarter-2025-financial-results-and-highlights-for-neffy] (SPRY [https://seekingalpha.com/symbol/SPRY]): Q3 GAAP EPS of -$0.52 misses by $0.05.
* Revenue of $32.5M (+1470.0% Y/Y) beats by $3.82M.
* As of September 30, 2025, ARS Pharma had cash, cash equivalents, and short-term investments of $288.2 million, with 98,844,178 shares of common stock outstanding.

MORE ON ARS PHARMACEUTICALS

* ARS Pharmaceuticals: A Significant Upside Is Expected From neffy [https://seekingalpha.com/article/4825008-ars-pharmaceuticals-stock-significant-upside-expected-from-neffy-reiterate-buy]
* ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4813138-ars-pharmaceuticals-inc-spry-q2-2025-earnings-call-transcript]
* ARS Pharmaceuticals Q3 2025 Earnings Preview [https://seekingalpha.com/news/4518812-ars-pharmaceuticals-q3-2025-earnings-preview]
* ARS Pharma secures $250M loan to accelerate Neffy rollout [https://seekingalpha.com/news/4499963-ars-pharma-secures-250m-loan-to-accelerate-neffy-rollout]
* Seeking Alpha’s Quant Rating on ARS Pharmaceuticals [https://seekingalpha.com/symbol/SPRY/ratings/quant-ratings]